165P - Evaluation of the mutational profile in patients with metastatic non-small cell lung carcinoma diagnosed in a tertiary hospital which was performed by NGS method

Background

Lung cancer is the most common cancer in men (14.3%) and 3rd most common cancer in female (8.4%) but account for overall highest cancer related mortality (18%). In India, lung cancer is 4th most common cancer both in incidence and cancer related death. NSCLC is the most common type accounting about 80-85% cases and among these adenocarcinoma accounts for more than half and is further defined according to different molecular subtypes by the identification of oncogenic drivers. With recent advances in the knowledge of NSCLC biology, various oncogenic driver mutations are identified which causes aberrant activation of intracellular signaling pathways associated with the sustained growth of lung cancer cells. Research objectives: Evaluation the mutational profile of NSCLC with broad panel-based next-generation sequencing.

Methods

The study was a hospital based prospective, cross sectional descriptive study conducted at a tertiary care center in Northeast India done during the period from 1^st january,2022 to 31st December,2022. Ninteen cases of histologically proven meatstatic NSCLC in core biopsy were included in this study.

Results

The age of patients with NSCLC in our study ranged from 48 to 80 years with mean age of 64.36(+/-9.82) years. Majority of the patients in our study were from the age category 71-80 years (37%) Male to female ratio was 19:1 (95% vs 5%). 73.3% of cases were chronic smokers while 26.3% were nonsmokers with smoker non-smoker ratio of 2.79:1.100% of cases presented in late stage (Stages IV). Regarding biomarker profile of NSCLC in our study, EGFR mutation positivity was seen in 10.5%.ALK rearrangement was positive in 5.3% of patients. In our study PD-L1 expression positivity was57.9% and among these patients,18.2% has TPS>50% whereas 81.8% showed TPS<50%.

Conclusions

Adenocarcinoma is the predominant histological subtype of NSCLC in the region of NE India, with a high proportion of cases harboring EGFR mutation. Moreover, NSCLC is characterized with unique mutations and cannot be generalized in larger context. So, study with larger sample size should be encouraged for evaluation of molecular profile of NSCLC in this region.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Assam Medical College, Dibrugarh.

Funding

Has not received any funding.

Disclosure

The author has declared no conflicts of interest.